Edition:
United States

Vical Inc (VICL.PH)

VICL.PH on Philadelphia Stock Exchange

2.16USD
24 Feb 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.16
Open
$2.19
Day's High
$2.19
Day's Low
$2.16
Volume
220
Avg. Vol
263
52-wk High
$4.77
52-wk Low
$2.16

Latest Key Developments (Source: Significant Developments)

AnGes MG signs strategic business alliance agreement with Vical
Thursday, 8 Dec 2016 03:17am EST 

AnGes MG Inc <4563.T>:Says it signed strategic business alliance agreement for DNA vaccine, with Vical Inc on Dec. 8.  Full Article

Vical reports Q3 loss per share $0.24
Thursday, 3 Nov 2016 06:30am EDT 

Vical Inc - : Vical Inc says projecting net cash burn for 2016 between $8 million and $11 million . Vical reports third quarter 2016 financial results . Q3 loss per share $0.24 .Q3 revenue $2.6 million versus $5.0 million.  Full Article

Vical Q2 loss per share $0.14
Tuesday, 9 Aug 2016 06:30am EDT 

Vical Inc : Q2 loss per share $0.14 . Vical reports second quarter 2016 financial results . Q2 revenue $4.1 million versus $4.2 million .Projecting net cash burn for 2016 between $8 million and $11 million.  Full Article

Vical announces $7.8 mln equity investment by partner Anges MG
Monday, 1 Aug 2016 06:30am EDT 

Vical Inc : Vical announces $7.8 million equity investment by partner, Anges MG . Shares are being sold at a price of $4.24 per share .With new investment, Anges' equity position in Vical will increase from 2.4% to approximately 18.6% of Vical's outstanding shares.  Full Article

Vical's phase 1/2 trial data shows bivalent vaccine imparts reduction in genital herpes lesions durable to 9 months
Monday, 20 Jun 2016 11:15am EDT 

Vical Inc : Initial top line 3-month data announced in june 2015 showed neither monovalent nor bivalent vaccine met primary endpoint of viral shedding rate reduction from baseline . Vaccine achieved statistically significant reduction in prospectively defined secondary endpoint of genital lesion rate at 3 months versus baseline . Plan to initiate a phase 2 trial of bivalent vaccine during second half of 2016 . Maintain our guidance for net cash burn of between $8 million and $11 million during 2016 .Vical's phase 1/2 trial data presented at asm 2016 shows bivalent vaccine imparts reduction in genital herpes lesions durable to 9 months.  Full Article

Vical Inc says FDA Grants Vical Orphan Drug Designation for VL-2397
Wednesday, 6 Jan 2016 06:30am EST 

Vical Inc:Says FDA Grants Vical Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis.Plan to initiate a Phase 1 clinical trial in the first half of 2016.  Full Article

Vical Inc reports top-line results from phase 1/2 trial of therapeutic genital herpes vaccine
Monday, 22 Jun 2015 04:11pm EDT 

Vical Inc:Says the primary endpoint of shedding rate was not met.Says both the monovalent and bivalent vaccines were generally well tolerated.Says are also moving our in-licensed antifungal compound toward a phase 1 trial initiation during the first half of 2016.Enrollment is complete in the phase 2 solid organ transplant trial;on track for data during the second half of 2016.Bivalent vaccine achieved statistically significant reductions in the rate of genital lesions.  Full Article

More From Around the Web

BRIEF-Vical reports Q3 loss per share $0.24

* Vical Inc says projecting net cash burn for 2016 between $8 million and $11 million